Pharmacy-based screening to detect persons at elevated risk of type 2 diabetes: a cost-utility analysis

Table 1 Costs applied in the Markov model, their distributions and the values used to estimate the distributions. Costs before 2019 have been discounted to the latest values

Parameter	Value (€) (variation)	Distribution	Distribution values used in PSA (€) Mean (SE)	Source
Cost of recruitment*	24.5€ (18.4–30.6)	Gamma	24.5 (3)	Based on own results
Cost of intervention*	650 € (488–813)	Gamma	650 (83)	[21]
Additional health care costs of T2D excluding basic health care*	3315 € (2486–4144)	Gamma	3315 (423)	[22]
Cost of T2D complications*	4401€ (3301–5501)	Gamma	4401 (561)	[23]
Costs from productivity losses due to T2D ^a*	7632€ (5724–9540)	Gamma	7632 (974)	[24]
Additional T2D health care costs for basic health care	551 (SD 575) for men 533 (SD 635) for women	Gamma	Men = 551 (9.53) Women = 533 (9.82)	Based on own results
Additional medication costs of T2D*	584 (438–730)	Gamma	584 (74)	[25]

^a for persons under 65 years old *For variables without available confidence interval, a variation of ±25% has been used as an estimate. SE was calculated separately for additional T2D health care costs for basic health care. In other these cases, SE has been calculated as:
\( SE=\frac{Mean\ast 1.25- Mean\ast 0.75}{2\ast 1.96} \)

ISSN: 1472-6963